Seres Therapeutics, Inc. (MCRB) Financials
Key financial figures for Seres Therapeutics, Inc. (Q3 2026).
Seres Therapeutics, Inc. reported revenue of $736.0 thousand for Q2 FY2026. Net income was $4.6 million, or $0.47 per share. Operating margin came to -2890.35%. Free cash flow for the period was -$22.4 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Seres Therapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $593K
- Net Income
- -$16M
- EPS
- $-1.63
- Total Assets
- $66M
- Operating Cash Flow
- -$10M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $736K | $5M | $0.47 | -2890.35% | -$22M |
| Q1 FY2026 | $358K | -$20M | -$2.08 | -5839.94% | -$16M |
| Q4 FY2025 | $438K | -$15M | -$1.73 | -4423.97% | -$15M |
| Q3 FY2025 | $351K | $8M | $0.94 | -6403.7% | $2M |
| Q2 FY2025 | $0 | -$20M | -$2.27 | -$13M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $789K | $6M | $0.64 | -11910.14% | $865K |
| FY2024 | $0 | -$147M | -$18.86 | -$149M | |
| FY2023 | $0 | -$114M | -$17.77 | -$125M |
Frequently asked questions
What was Seres Therapeutics, Inc.'s revenue last quarter?
Seres Therapeutics, Inc. reported revenue of $736.0 thousand for Q2 FY2026.
Is Seres Therapeutics, Inc. profitable?
Yes. Seres Therapeutics, Inc. reported net income of $4.6 million for Q2 FY2026, a net margin of 622.42% on revenue.
How has Seres Therapeutics, Inc.'s margin trended?
Operating margin was -2890.35% in Q2 FY2026. The quarter by quarter series is on the SentiSense financials page.
When does Seres Therapeutics, Inc. report next?
Seres Therapeutics, Inc. is scheduled to report Q3 2026 results on 2026-11-04. The company has confirmed that date.
Full income statement, balance sheet and cash flow for Seres Therapeutics, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.